📰 Psychedelics News
Curated updates on microdosing, research, policy, and community.
Filters
100+ speakers confirmed for Breaking Convention 2025!
Names and talk titles for your delight
Correcting the Record: Addressing The New York Times’ Deceptive Coverage of Psymposia
Rather than unpacking the actual causes of Lykos Therapeutics' disastrous Phase 3 trials and FDA rejection, The New York Times produced a work of fictitious propaganda that prioritizes corporate interests over public ...
Correcting the Record: What The New York Times Got Wrong
In response to the The New York Times February 4 article, "How a Leftist Activist Group Helped Torpedo a Psychedelic Therapy," Psymposia requested corrections to numerous errors and false accusations. The po...
Compound harnesses cannabis' pain-relieving properties without side effects
Researchers have developed a compound that relieves pain in mice but doesn't affect the brain, thereby avoiding mind-altering side effects and abuse potential. The custom-designed molecule, derived from cannabis, may ...
Only 46 days until Breaking Convention 2025!!!
Last few on-campus accommodation rooms remaining
Our favorite investable areas in brain health with PsyMed Ventures
Greg and Matias chat with Brooks about the evolution of PsyMed Ventures’ investment strategy: a human-first approach to neurotech, novel therapeutics, consumer health, and precision neuroscience
Researchers achieve total synthesis of ibogaine
Researchers have achieved total chemical synthesis of the psychoactive compound ibogaine and its analogs from pyridine. The discovery will make it easier to explore the therapeutic possibilities of ibogaine.
Temporal Interference: The Future of Brain Stimulation with Nir Grossman
Business Trip by PsyMed Ventures, a podcast exploring the future of mental and brain health & the startups building it
This is your last call to take part in Europe's largest multidisciplinary conference on psychedelics!
DEADLINE 19th January!!!
Psychedelic drug therapy may address mental health concerns in people with cancer and addiction
One or two doses of psilocybin, a compound found in psychedelic mushrooms, may improve the mental health of cancer patients when accompanied by psychotherapy, a new study suggests. A second new study found that treatm...
The State of Autism Part 2 with Jim Adams of Gut-Brain-Axis Therapeutics Inc.
Business Trip by PsyMed Ventures, a podcast exploring the future of mental and brain health & the startups building it
Solstice greetings!
Stuck for gift ideas? Psychedelic Santa is waiting...
Discouraged zebrafish help reveal how ketamine works in the brain
By taking advantage of a 'giving up' behavior exhibited by zebrafish, the ability to image the fish's entire brain, and a unique virtual reality system, a team of researchers found where ketamine acts in the zebrafish...
Updates on 2025 at the APS with our VP-Jess
A end of year thank-you-very-much and 2025 update with Australian Psychedelic Society, Vice President Jess Maude